Clinical trials: Screen Time
Colo-rectal Cancer
Motility of the Check-cap's MD1 Colon Capsule in Subjects Following Colon Rectal Cancer Screening by Colonoscopy
To monitor the Whole Gut Transit Time and repeatability of the motility of MD1 capsules in the colon of subjects with known polyps and in healthy subjects. Multi-Center, Open, Home Monitoring, Prospective Study.
- Trial name
- NCT03785665
- Testing
- MDI
- Where
- Israel
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Check-Cap Ltd.
Healthy
Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days
The objective of this study is to evaluate the effect on corneal endothelial cell density changes when ISV-403 is administered for five (5) days compared to no drug treatment, in healthy subjects.
- Trial name
- NCT01120418
- Testing
- Besifloxacin Ophthalmic Suspension 0.6%
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Screen Time
Characterization of Smartphone-related Diseases Using the Phonix Care Application
The goal of this observational study is to describe how adolescents and young adults use screens in their daily lives and to identify different profiles of screen use ranging from low to excessive.
- Trial name
- PHX_2022_1 (NCT07293208)
- Testing
- PhonixDiag Smartphone Monitoring Tool
- Where
- France
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Phonix Health
Transfusion Transmitted Babesiosis
Babesia Testing in Blood Donors
Both prospective and retrospective (look back) study of blood donors for laboratory evidence of babesia microti infection. Two laboratory methodologies will be utilized: 1.
- Trial name
- NCT01528449
- Testing
- B.microti diagnostic blood tests
- Where
- United States
- Volunteers
- 90,116 people, healthy volunteers welcome
- Sponsor
- Imugen
Healthy
First in Man Clinical Study to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of CM3.1-AC100
A first time in man, phase I study to assess the safety, tolerability and pharmacokinetics of single ascending doses of CM3.1-AC100 in healthy male volunteers.
- Trial name
- NCT01028521
- Testing
- CM3.1-AC100
- Where
- Germany
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- CellMed AG, a subsidiary of BTG plc.
Screening Colonoscopy, Surveillance Colonoscopy
Study to Evaluate the Diagnostic Performance of of MAGENTIQ-COLO During Colonoscopy.
This is an international, multicenter, study to evaluate the diagnostic performance of the CADx polyp sizing modality of the MAGENTIQ-COLO.
- Trial name
- NCT06568523
- Testing
- MAGENTIQ-COLO.
- Where
- 5 sites in United States, Israel and 1 more
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Magentiq Eye LTD